Hormonal
Obesity-related complications (ORCs) such as hypertension, diabetes, and dyslipidemia are the primary drivers for initiating pharmacological obesity treatment, often delaying preventative care until complications are present and uncontrolled.
If you have obesity, do not wait for complications like high blood pressure or diabetes to seek treatment. The current system often delays medication until these issues arise, but early intervention with Obesity Management Medications (OMMs) can help control these complications and improve quality of life. Discuss preventative treatment with your doctor, especially if you have a family history of these conditions.
Medical treatment for obesity was often delayed until ORCs developed, suggesting that preventative healthcare measures are not the norm for PwO in Canada.
Why this rating
Cross-sectional survey data with potential selection bias (high SES, those accessing care), but large sample size for a real-world observation.
Source
Management and impact of obesity in Canada: A real-world survey of people with obesity and their physicians
Jennifer M. Glass et al. · Obesity Pillars · 2025
DOI 10.1016/j.obpill.2025.100171
More from this paper
- Obesity significantly impairs work productivity and daily activities, with over 25% of work time impaired due to obesity status, and this impairment is greater in patients with obesity-related complications.Moderate
- Access to obesity treatment in Canada is inequitable, with patients having high socioeconomic status being overrepresented in treatment programs compared to the general population of people with obesity, who are more likely to have lower socioeconomic status.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →